Key result
Oral administration of the ACE2 activator XNT for 30 days improved baroreflex bradycardia sensitivity by ≈76% and parasympathetic tone by ≈205% in diabetic rats.
Why the study?
Does XNT improve cardiovascular autonomic dysfunction in diabetic rats?
Does XNT improve cardiovascular autonomic dysfunction in diabetic rats?
Oral administration of the ACE2 activator XNT improves cardiovascular autonomic and cardiac dysfunction in a rat model of type 1 diabetes.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for ACE2 activation in diabetic autonomic neuropathy; requires human trials before any clinical consideration.
In this study, we evaluated whether the activation of endogenous angiotensin-converting enzyme 2 (ACE2) would improve the cardiovascular autonomic dysfunction of diabetic rats. Ten days after induction of type 1 diabetes (streptozotocin, 50 mg kg(-1) i.v.), the rats were treated orally with 1-[(2-dimethylamino)ethylamino]-4-(hydroxymethyl)-7-[(4-methylphenyl) sulfonyl oxy]-9H-xanthene-9-one (XNT), a newly discovered ACE2 activator (1 mg kg(-1) day(-1)), or saline (equivalent volume) for 30 days. Autonomic cardiovascular parameters were evaluated in conscious animals, and an isolated heart preparation was used to analyse cardiac function. Diabetes induced a significant decrease in the baroreflex bradycardia sensitivity, as well as in the chemoreflex chronotropic response and parasympathetic tone. The XNT treatment improved these parameters by ≈ 76% [0.82 ± 0.09 versus 1.44 ± 0.17 Ratio between changes in pulse interval and changes in mean arterial pressure (ΔPI/ΔmmHg)], ∼85% (-57 ± 9 versus -105 ± 10 beats min(-1)) and ≈ 205% (22 ± 2 versus 66 ± 12 beats min(-1)), respectively. Also, XNT administration enhanced the bradycardia induced by the chemoreflex activation by v 74% in non-diabetic animals (-98 ± 16 versus -170 ± 9 Δbeats min(-1)). No significant changes were observed in the mean arterial pressure, baroreflex tachycardia sensitivity, chemoreflex pressor response and sympathetic tone among any of the groups. Furthermore, chronic XNT treatment ameliorated the cardiac function of diabetic animals. However, the coronary vasoconstriction observed in diabetic rats was unchanged by ACE2 activation. These findings indicate that XNT protects against the autonomic and cardiac dysfunction induced by diabetes. Thus, our results provide evidence for the viability and effectiveness of oral administration of an ACE2 activator for the treatment of the cardiovascular autonomic dysfunction caused by diabetes.
No takes yet. Share an insight, caveat, or question.
Murça et al. (2012) studied Type 1 diabetes with cardiovascular autonomic dysfunction. XNT (ACE2 activator) vs. Saline was evaluated on Baroreflex bradycardia sensitivity. Oral administration of the ACE2 activator XNT for 30 days improved baroreflex bradycardia sensitivity by ≈76% and parasympathetic tone by ≈205% in diabetic rats.
Synapse has enriched 10 related papers. Consider them for comparative context: